© 2020 MJH Life Sciences and OncLive. All rights reserved.
© 2020 MJH Life Sciences™ and OncLive. All rights reserved.
August 5th 2020
Michael Wang, MD, discusses the importance of additional CAR T-cell therapy research in mantle cell lymphoma.
August 3rd 2020
Michael Wang, MD, discusses the safety profile of the CAR T-cell therapy brexucabtagene autoleucel in relapsed/refractory mantle cell lymphoma.
July 24th 2020
Michael Wang, MD, a professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses the FDA approval of brexucabtagene autoleucel (Tecartus; formerly KTE-X19) in mantle cell lymphoma (MCL).
June 26th 2020
Michael Wang, MD, discusses the efficacy of KTE-X19 in low- and high-risk patients with relapsed/refractory mantle cell lymphoma as part of the phase 2 ZUMA-2 trial.